In an article published online today in the journal Urologic Oncology, urologist Ralph de Vere White and medical oncologist Primo Lara, Jr. of the UC Davis Comprehensive Cancer Center describe a framework for urology and medical oncology interactions to enhance patient care, improve outcomes and yield clinical research advances…
These new proteins have not previously been associated with T-cell responses. T-cells help fight infections but also can trigger autoimmune diseases or graft vs…
The preliminary results of a phase 1B study were presented by Dr. Edward Garon, director of thoracic oncology at UCLA’s Jonsson Comprehensive Cancer Center, on Tuesday October 29 at the 15th World Conference on Lung Cancer. The summit was held by the International Association for the Study of Lung Cancer, in Sydney, Australia…
Pancreatic cancer is one of the deadliest types of cancer, with a five-year survival rate of just 6 percent. …
Now adrenal cancer researchers at the University of Michigan Comprehensive Cancer Center are seeing the results of their laboratory studies translate to a clinical trial to test a potential new therapy in patients. Researchers Tom Kerppola, Ph.D., and Gary Hammer, M.D., Ph.D., collaborated to test a new compound, ATR-101, in cell lines and mice. …
Their study, published today in the Proceedings of the National Academy of Sciences (PNAS) suggests the compound, already shown to be safe for humans, may protect normal tissues during radiation therapy for cancer treatment and prevent or mitigate sickness caused by radiation exposure. The compound, known as DIM (3,3′-diindolylmethane), previously has been found to have cancer preventive properties. "DIM has been studied as a cancer prevention agent for years, but this is the first indication that DIM can also act as a radiation protector," says the study’s corresponding author, Eliot Rosen, MD, PhD, of Georgetown Lombardi Comprehensive Cancer Center. For the study, the researchers irradiated rats with lethal doses of gamma ray radiation…
source : http://www.foxnews.com/health/2013/07/03/breast-cancer-gene-testing-most-moms-tell-kids-results/
Researchers have long understood the function of the protein, Caveolin-1 (Cav-1), in prostate cancer, including its role in treatment resistance and disease aggressiveness. However, prior to this study, little was known about the role of Cav-1 within the stroma. The study, published in the Journal of Pathology, found that a decreased level of the Cav-1 protein in the stroma indicated tumor progression — a function opposite to the known role of Cav-1 within a tumor…
Results of the study will be presented at the ATS 2013 International Conference. "Lung cancer is the leading cause of cancer-related death and has a poor survival rate," said Sue Yoon, nurse practitioner at VA Boston HealthCare West Roxbury Division. "Most of our veterans in these ages have a heavy smoking history and early screening is desirable to improve outcomes. Our study was undertaken to learn how often we would discover significant abnormalities and how to adapt our existing processes and interdisciplinary approaches to accommodate additional patients." Conducted according to guidelines set forth by the National Comprehensive Cancer Network (NCCN), the study was based in part on the results of the National Lung Cancer Screening Trial (NLST) which found that LDCT resulted in a 20 percent reduction of lung cancer mortality compared to chest x-ray among heavy smokers aged 55 to 74 years. …